Psoriasis

The Lancet

Volumn 386, Issue 9997, 2015, Pages 983-994

  Boehncke, Wolf Henning ^a,b   Schön, Michael P ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; COLECALCIFEROL; CORTICOSTEROID; GLUCOCORTICOID; INTERLEUKIN 23; VITAMIN D DERIVATIVE;

ADAPTIVE IMMUNITY; AWARENESS; CHILDHOOD DISEASE; CHRONICITY; CLINICAL FEATURE; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISABILITY; EARLY DIAGNOSIS; FEEDBACK SYSTEM; GENETICS; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; NAIL PSORIASIS; PATHOGENESIS; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; PUVA; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TH17 CELL; METABOLISM;

HUMANS; PSORIASIS;

EID: 84941421180     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61909-7     Document Type: Review

References (137)

1. SR Rapp, SR Feldman, ML Exum, AB Fleischer Jr, DM Reboussin Psoriasis causes as much disability as other major medical diseases J Am Acad Dermatol 41 1999 401 407
2. L Dubertret, U Mrowietz, A Ranki the EUROPSO Patient Survey Group European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey Br J Dermatol 155 2006 729 736
3. WHO World psoriasis day - document EB133.R2, agenda item 6.2. May 30, 2013 http://apps.who.int/gb/ebwha/pdf-files/EB133/B133-R2-en.pdf (accessed March 13, 2015).
4. E Christophers Psoriasis - epidemiology and clinical spectrum Clin Exp Dermatol 26 2001 314 320
5. M Augustin, G Glaeske, MA Radtke, E Christophers, K Reich, I Schäfer Epidemiology and comorbidity of psoriasis in children Br J Dermatol 162 2010 633 636
6. MP Schön, WH Boehncke Psoriasis N Engl J Med 352 2005 1899 1912
7. CC Jacobson, S Kumar, AB Kimball Latitude and psoriasis prevalence J Am Acad Dermatol 65 2011 870 873
8. N Balato, L Di Costanzo, C Patruno, A Patrì, F Ayala Effect of weather and environmental factors on the clinical course of psoriasis Occup Environ Med 70 2013 600
9. CEM Griffiths, JNWN Barker Pathogenesis and clinical features of psoriasis Lancet 370 2007 263 271
10. FO Nestle, DH Kaplan, J Barker Psoriasis N Engl J Med 361 2009 496 509
11. D Hägg, M Eriksson, A Sundström, M Schmitt-Egenolf The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men PLoS One 8 2013 e63619
12. J Ortonne, S Chimenti, T Luger, L Puig, F Reid, RM Trüeb Scalp psoriasis: European consensus on grading and treatment algorithm J Eur Acad Dermatol Venereol 23 2009 1435 1444
13. U Runne Alopecia psoriatica. Charakteristika eines bisher negierten Krankheitsbildes Hautarzt 44 1993 691 692
14. K Reich Approach to managing patients with nail psoriasis J Eur Acad Dermatol Venereol 23 suppl 1 2009 15 21
15. R Baran The burden of nail psoriasis: an introduction Dermatology 221 suppl 1 2010 1 5
16. ES Tan, WS Chong, HL Tey Nail psoriasis: a review Am J Clin Dermatol 13 2012 375 388
17. K Sugiura The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants J Dermatol Sci 74 2014 187 192
18. S Marrakchi, P Guigue, BR Renshaw et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis N Engl J Med 365 2011 620 628
19. C Joyau, G Veyrac, V Dixneuf, P Jolliet Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 30 2012 700 706
20. E Shmidt, DA Wetter, SB Ferguson, MR Pittelkow Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010 J Am Acad Dermatol 67 2012 e179 e185
21. P Besgen, P Trommler, S Vollmer, JC Prinz Ezrin, maspin, peroxiredoxin 2, and heat shock protein 27: potential targets of a streptococcal-induced autoimmune response in psoriasis J Immunol 184 2010 5392 5402
22. BA Martin, RJ Chalmers, NR Telfer How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? Arch Dermatol 132 1996 717 718
23. C Fotiadou, E Lazaridou, D Ioannides Management of psoriasis in adolescence Adolesc Health Med Ther 5 2014 25 34
24. M Ståhle, N Atakan, W-H Boehncke et al. Juvenile psoriasis and its clinical management: a European expert group consensus J Dtsch Dermatol Ges 8 2010 812 818
25. KH Basavaraj, NM Ashok, R Rashmi, TK Praveen The role of drugs in the induction and/or exacerbation of psoriasis Int J Dermatol 49 2010 1351 1361
26. V Mahler, T Diepgen, C Skudlik et al. Psoriasis predisposition and occupational triggering factors in the appraisal of occupational medical expertises J Dtsch Dermatol Ges 12 2014 519 529
27. L Fry, BS Baker Triggering psoriasis: the role of infections and medications Clin Dermatol 25 2007 606 615
28. J Schmitt, G Wozel The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis Dermatology 210 2005 194 199
29. RG Langley, CN Ellis Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment J Am Acad Dermatol 51 2004 563 569
30. JC Henes, E Ziupa, M Eisfelder et al. High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study Rheumatol Int 34 2014 227 234
31. LC Coates, T Aslam, F Al Balushi et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study) Br J Dermatol 168 2013 802 807
32. WH Boehncke, S Boehncke, MP Schön Managing comorbid disease in patients with psoriasis BMJ 340 2010 b5666
33. BJ Nickoloff, JZ Qin, FO Nestle Immunopathogenesis of psoriasis Clin Rev Allergy Immunol 33 2007 45 56
34. R Sabat, S Philipp, C Höflich et al. Immunopathogenesis of psoriasis Exp Dermatol 16 2007 779 798
35. JT Elder Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis Genes Immun 10 2009 201 209
36. JT Elder, AT Bruce, JE Gudjonsson et al. Molecular dissection of psoriasis: integrating genetics and biology J Invest Dermatol 130 2010 1213 1226
37. FO Nestle, C Conrad, A Tun-Kyi et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production J Exp Med 202 2005 135 143
38. RM Locksley, N Killeen, MJ Lenardo The TNF and TNF receptor superfamilies: integrating mammalian biology Cell 104 2001 487 501
39. A Di Cesare, P Di Meglio, FO Nestle The IL-23/Th17 axis in the immunopathogenesis of psoriasis J Invest Dermatol 129 2009 1339 1350
40. L Steinman A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage Nat Med 13 2007 139 145
41. MA Lowes, T Kikuchi, J Fuentes-Duculan et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells J Invest Dermatol 128 2008 1207 1211
42. MF Neurath IL-23: a master regulator in Crohn disease Nat Med 13 2007 26 28
43. H Kebir, K Kreymborg, I Ifergan et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation Nat Med 13 2007 1173 1175
44. E Bettelli, M Oukka, VKT Kuchroo T(H)-17 cells in the circle of immunity and autoimmunity Nat Immunol 8 2007 345 350
45. C Parham, M Chirica, J Timans et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R J Immunol 168 2002 5699 5708
46. TP Singh, MP Schön, K Wallbrecht, A Gruber-Wackernagel, XJ Wang, P Wolf Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis PLoS One 8 2013 e51752
47. I Kryczek, AT Bruce, JE Gudjonsson et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis J Immunol 181 2008 4733 4741
48. RR Keijsers, AG Hendriks, PE van Erp et al. In vivo induction of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing RORγt and IL-17 J Invest Dermatol 134 2014 1276 1284
49. MP Schön The plot thickens while the scope broadens: a holistic view on IL-17 in psoriasis and other inflammatory disorders Exp Dermatol 23 2014 804 806
50. AM Lin, CJ Rubin, R Khandpur et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis J Immunol 187 2011 490 500
51. AS Büchau, RL Gallo Innate immunity and antimicrobial defense systems in psoriasis Clin Dermatol 25 2007 616 624
52. C Costa, J Incio, R Soares Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10 2007 149 166
53. C Rosenberger, C Solovan, AD Rosenberger et al. Upregulation of hypoxia-inducible factors in normal and psoriatic skin J Invest Dermatol 127 2007 2445 2452
54. I Teige, H Hvid, L Svensson, PH Kvist, K Kemp Regulatory T cells control VEGF-dependent skin inflammation J Invest Dermatol 129 2009 1437 1445
55. PM Elias, J Arbiser, BE Brown et al. Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia: implications for the pathogenesis of psoriasis Am J Pathol 173 2008 689 699
56. HS Young, AM Summers, M Bhushan, PE Brenchley, CE Griffiths Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset J Invest Dermatol 122 2004 209 215
57. MP Schön, TM Zollner, W-H Boehncke The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders J Invest Dermatol 121 2003 951 962
58. R Heidenreich, M Röcken, K Ghoreschi Angiogenesis: the new potential target for the therapy of psoriasis? Drug News Perspect 21 2008 97 105
59. JR Zibert, K Wallbrecht, M Schön et al. Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions J Clin Invest 121 2011 410 421
60. JM Hall, D Cruser, A Podawiltz, DI Mummert, H Jones, ME Mummert Psychological stress and the cutaneous immune response: roles of the HPA axis and the sympathetic nervous system in atopic dermatitis and psoriasis Dermatol Res Pract 2012 2012 403908
61. EN Madva, RD Granstein Nerve-derived transmitters including peptides influence cutaneous immunology Brain Behav Immun 34 2013 1 10
62. K Reich The concept of psoriasis as a systemic inflammation: implications for disease management J Eur Acad Dermatol Venereol 26 suppl 2 2012 3 11
63. EM Farber, ML Nall The natural history of psoriasis in 5,600 patients Dermatologica 148 1974 1 18
64. T Henseler, E Christophers Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris J Am Acad Dermatol 13 1985 450 456
65. RP Nair, PE Stuart, I Nistor et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene Am J Hum Genet 78 2006 827 851
66. RC Trembath, RL Clough, JL Rosbotham et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis Hum Mol Genet 6 1997 813 820
67. F Capon, AD Burden, RC Trembath, JN Barker Psoriasis and other complex trait dermatoses: from Loci to functional pathways J Invest Dermatol 132 2012 915 922
68. LC Tsoi, SL Spain, J Knight, et al, the Collaborative Association Study of Psoriasis (CASP) the Genetic Analysis of Psoriasis Consortium the Psoriasis Association Genetics Extension the Wellcome Trust Case Control Consortium 2 Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity Nat Genet 44 2012 1341 1348
69. F Capon, P Di Meglio, J Szaub et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis Hum Genet 122 2007 201 206
70. M Cargill, SJ Schrodi, M Chang et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes Am J Hum Genet 80 2007 273 290
71. AS Haider, MA Lowes, M Suàrez-Fariñas et al. Cellular genomic maps help dissect pathology in human skin disease J Invest Dermatol 128 2008 606 615
72. K Asumalahti, M Ameen, S Suomela et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis J Invest Dermatol 120 2003 627 632
73. P Rahman, RD Inman, WP Maksymowych, JP Reeve, L Peddle, DD Gladman Association of interleukin 23 receptor variants with psoriatic arthritis J Rheumatol 36 2009 137 140
74. F Villanova, P Di Meglio, FO Nestle Biomarkers in psoriasis and psoriatic arthritis Ann Rheum Dis 72 suppl 2 2013 ii104 ii110
75. N Wolf, M Quaranta, NJ Prescott et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease J Med Genet 45 2008 114 116
76. HL Hébert, FR Ali, J Bowes, CE Griffiths, A Barton, RB Warren Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy Br J Dermatol 166 2012 474 482
77. T Tejasvi, PE Stuart, V Chandran et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis J Invest Dermatol 132 2012 593 600
78. M Talamonti, E Botti, M Galluzzo et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab Br J Dermatol 169 2013 458 463
79. T Henseler, E Christophers Disease concomitance in psoriasis J Am Acad Dermatol 32 1995 982 986
80. S Gerdes, VA Zahl, H Knopf, M Weichenthal, U Mrowietz Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis Br J Dermatol 159 2008 1116 1123
81. K Abuabara, RS Azfar, DB Shin, AL Neimann, AB Troxel, JM Gelfand Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK Br J Dermatol 163 2010 586 592
82. Y Gupta, S Möller, D Zillikens, WH Boehncke, SM Ibrahim, RJ Ludwig Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease Exp Dermatol 22 2013 552 553
83. JM Gelfand, DB Shin, AL Neimann, X Wang, DJ Margolis, AB Troxel The risk of lymphoma in patients with psoriasis J Invest Dermatol 126 2006 2194 2201
84. P Gisondi, G Tessari, A Conti et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study Br J Dermatol 157 2007 68 73
85. JM Gelfand, AL Neimann, DB Shin, X Wang, DJ Margolis, AB Troxel Risk of myocardial infarction in patients with psoriasis JAMA 296 2006 1735 1741
86. L Mallbris, O Akre, F Granath et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients Eur J Epidemiol 19 2004 225 230
87. RJ Ludwig, C Herzog, A Rostock et al. Psoriasis: a possible risk factor for development of coronary artery calcification Br J Dermatol 156 2007 271 276
88. EJ Armstrong, CT Harskamp, AW Armstrong Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies J Am Heart Assoc 2 2013 e000062
89. EJ Samarasekera, JM Neilson, RB Warren, J Parnham, CH Smith Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis J Invest Dermatol 133 2013 2340 2346
90. T Xu, YH Zhang Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies Br J Dermatol 167 2012 1345 1350
91. AW Armstrong, SV Voyles, EJ Armstrong, EN Fuller, JC Rutledge A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis Exp Dermatol 20 2011 544 549
92. S Boehncke, R Salgo, J Garbaraviciene et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study J Eur Acad Dermatol Venereol 25 2011 1187 1193
93. WH Boehncke, S Boehncke, AM Tobin, B Kirby The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity Exp Dermatol 20 2011 303 307
94. EA Brezinski, MR Follansbee, EJ Armstrong, AW Armstrong Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review Curr Pharm Des 20 2014 513 528
95. T Ahern, AM Tobin, M Corrigan et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study J Eur Acad Dermatol Venereol 27 2013 1440 1443
96. C Horreau, C Pouplard, E Brenaut et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review J Eur Acad Dermatol Venereol 27 suppl 3 2013 12 29
97. EA Dowlatshahi, M Kavousi, T Nijsten et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study J Invest Dermatol 133 2013 2347 2354
98. T Nijsten, M Wakkee Complexity of the association between psoriasis and comorbidities J Invest Dermatol 129 2009 1601 1603
99. A Nast, WH Boehncke, U Mrowietz, et al, and the Deutsche Dermatologische Gesellschaft (DDG) the Berufsverband Deutscher Dermatologen (BVDD) S3 - guidelines on the treatment of psoriasis vulgaris (English version). Update J Dtsch Dermatol Ges 10 suppl 2 2012 S1 S95
100. S Hsu, KA Papp, MG Lebwohl, et al, and the National Psoriasis Foundation Medical Board Consensus guidelines for the management of plaque psoriasis Arch Dermatol 148 2012 95 102
101. D Pathirana, AD Ormerod, P Saiag et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris J Eur Acad Dermatol Venereol 23 suppl 2 2009 1 70
102. KA Papp, R Kaufmann, D Thaçi, C Hu, D Sutherland, P Rohane Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study J Eur Acad Dermatol Venereol 27 2013 e376 e383
103. RG Langley, BE Elewski, M Lebwohl for the ERASURE Study Group and FIXTURE Study Group Secukinumab in plaque psoriasis - results of two phase 3 trials N Engl J Med 24 371 2014 326 338
104. AR Mason, JM Mason, MJ Cork, H Hancock, G Dooley Topical treatments for chronic plaque psoriasis of the scalp: a systematic review Br J Dermatol 169 2013 519 527
105. JH Saurat, G Stingl, L Dubertret, et al, and the CHAMPION Study Investigators Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 2008 558 566
106. U Mrowietz, K Kragballe, K Reich et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus Arch Dermatol Res 303 2011 1 10
107. AC de Vries, NA Bogaards, L Hooft et al. Interventions for nail psoriasis Cochrane Database Syst Rev 1 2013 CD007633.
108. AB Gottlieb, AW Armstrong Psoriasis outcome measures: a report from the GRAPPA 2012 annual meeting J Rheumatol 40 2013 1428 1433
109. P Coto-Segura, N Eiris-Salvado, L González-Lara et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis Br J Dermatol 169 2013 783 793
110. AW Armstrong, CT Harskamp, EJ Armstrong The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies J Hypertens 31 2013 433 442
111. AW Armstrong, CT Harskamp, EJ Armstrong The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies Nutr Diabetes 2 2012 e54
112. IM Miller, C Ellervik, S Yazdanyar, GB Jemec Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors J Am Acad Dermatol 69 2013 1014 1024
113. W-J Gu, C-L Weng, Y-T Zhao, Q-H Liu, R-X Yin Psoriasis and risk of cardiovascular disease: a meta-analysis of cohort studies Int J Cardiol 168 2013 4992 4996
114. EA van der Voort, EM Koehler, EA Dowlatshahi et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study J Am Acad Dermatol 70 2014 517 524
115. E Daudén, S Castañeda, C Suárez, et al, and the Working Group on Comorbidity in Psoriasis Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis J Eur Acad Dermatol Venereol 27 2013 1387 1404
116. J Wohlrab, G Fiedler, S Gerdes et al. Recommendations for detection of individual risk for comorbidities in patients with psoriasis Arch Dermatol Res 305 2013 91 98
117. A Amherd-Hoekstra, H Näher, HM Lorenz, AH Enk Psoriatic arthritis: a review J Dtsch Dermatol Ges 8 2010 332 339
118. DJ Veale, O FitzGerald Psoriatic arthritis - pathogenesis and epidemiology Clin Exp Rheumatol 20 suppl 28 2002 S27 S33
119. GK Hansson Inflammation, atherosclerosis, and coronary artery disease N Engl J Med 352 2005 1685 1695
120. JA Kim, M Montagnani, KK Koh, MJ Quon Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms Circulation 113 2006 1888 1904
121. O Ahlehoff, L Skov, G Gislason et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study J Intern Med 273 2013 197 204
122. AW Armstrong, EA Brezinski, MR Follansbee, EJ Armstrong Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review Curr Pharm Des 20 2014 500 512
123. C Ryan, NJ Korman, JM Gelfand et al. Research gaps in psoriasis: opportunities for future studies J Am Acad Dermatol 70 2014 146 167
124. JH Hoffmann, M Hartmann, AH Enk, EN Hadaschik Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction Br J Dermatol 165 2011 1355 1358
125. MP Schön Predicting the unpredictable: autoantibody profile as parameter to foretell individual responses to infliximab treatment? Br J Dermatol 165 2011 1160 1161
126. L Hsu, BT Snodgrass, AW Armstrong Antidrug antibodies in psoriapansis: a systematic review Br J Dermatol 170 2014 261 273
127. AS Raut, RH Prabhu, VB Patravale Psoriasis clinical implications and treatment: a review Crit Rev Ther Drug Carrier Syst 30 2013 183 216
128. G Wozel Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas Clin Dermatol 26 2008 448 459
129. M Sticherling, M Augustin, WH Boehncke et al. Therapy of psoriasis in childhood and adolescence - a German expert consensus J Dtsch Dermatol Ges 9 2011 815 823
130. N Xu, F Meisgen, LM Butler et al. MicroRNA-31 is overexpressed in psoriasis and modulates inflammatory cytokine and chemokine production in keratinocytes via targeting serine/threonine kinase 40 J Immunol 190 2013 678 688
131. MA Lowes, CB Russell, DA Martin, JE Towne, JG Krueger The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses Trends Immunol 34 2013 174 181
132. MP Schön Animal models of psoriasis: a critical appraisal Exp Dermatol 17 2008 703 712
133. S Kumari, MC Bonnet, MH Ulvmar et al. Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis-like skin inflammation in mice Immunity 39 2013 899 911
134. M Augustin, K Krüger, MA Radtke, I Schwippl, K Reich Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany Dermatology 216 2008 366 372
135. M Augustin, C Spehr, MA Radtke et al. German psoriasis registry PsoBest: objectives, methodology and baseline data J Dtsch Dermatol Ges 12 2014 48 57
136. K Woth, C Prein, K Steinhorst, S Diehl, W-H Boehncke, C Buerger Endothelial cells are highly heterogeneous at the level of cytokine-induced insulin resistance Exp Dermatol 22 2013 714 718
137. C Buerger, B Richter, K Woth et al. Interleukin-1β interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis J Invest Dermatol 132 2012 2206 2214